BCCA7693
/ adMare BioInnovations, BC Cancer Agency
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
BCCA7693 - A novel, orally bioavailable DNA-PK inhibitor demonstrates efficacy with targeted therapeutics by inhibiting the development of acquired resistance
(AACR 2026)
- "Abstract is embargoed at this time."
Clinical • Late-breaking abstract • Preclinical • Oncology
1 to 1
Of
1
Go to page
1